Publication | Closed Access

Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls

Neurodegenerative DiseasesAlzheimer's DiseaseMechanism Phase 0Brain β-Amyloid BurdenBiomarkersFlorbetaben Pet TrialNeurologyNeuroscienceNeurodegenerationAging-associated DiseaseBrain PathologyMedicine